About: Adjunct immunotherapies for the management of severely ill COVID-19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Adjunct immunotherapies for the management of severely ill COVID-19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Adjunct immunotherapies for the management of severely ill COVID-19 patients
Creator	Bayry, L Gilardin, A Kaveri, S Sakuntabhai, S
Source	Elsevier; Medline; PMC
abstract	Abstract Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has infected millions with more than 181,000 fatal cases as of 22nd April 2020. Currently, there are no specific COVID-19 therapies. Most patients depend on mechanical ventilation. Current COVID-19 data clearly highlight that cytokine storm and activated immune cell migration to the lungs characterize the early immune response to COVID-19 that causes severe lung damage and development of acute respiratory distress syndrome. In view of uncertainty associated with immunosuppressive treatments such as corticosteroids and their possible secondary effects, including risks of secondary infections, we suggest immunotherapies as an adjunct therapy in severe COVID-19 cases. Such immunotherapies based on inflammatory cytokine neutralization, immunomodulation and passive viral neutralization, not only reduce inflammation, inflammation-associated lung damage, or viral load, but could also prevent intensive care unit hospitalization and dependency on mechanical ventilation both of which are limited resources.
has issue date	2020-04-30(xsd:dateTime)
bibo:doi	10.1016/j.xcrm.2020.100016
bibo:pmid	32562483
has license	els-covid
sha1sum (hex)	d6ad8c9b0086b05f7436e6eed4831c0b722c50ef
schema:url	https://doi.org/10.1016/j.xcrm.2020.100016
resource representing a document's title	Adjunct immunotherapies for the management of severely ill COVID-19 patients
has PubMed Central identifier	PMC7190525
has PubMed identifier	32562483
schema:publication	Cell reports medicine
resource representing a document's body	covid:d6ad8c9b0086b05f7436e6eed4831c0b722c50ef#body_text
is schema:about of	named entity 'secondary' named entity 'secondary' named entity 'passive' named entity 'data' named entity 'cytokine storm' named entity 'mechanical ventilation' named entity 'immunosuppressive' named entity 'Adjunct' named entity 'BASED' named entity 'APRIL' named entity 'CYTOKINE STORM' named entity 'CURRENTLY' named entity 'SEVERE COVID-19' named entity 'SPECIFIC' named entity 'immune cell' named entity 'viral' named entity 'specific' named entity 'neutralization' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'damage' named entity 'severe' named entity 'acute respiratory distress syndrome' named entity 'COVID-19' named entity 'ill' named entity 'inflammatory cytokine' named entity 'immunosuppressive' named entity 'intensive care unit' named entity 'inflammation' named entity 'SARS-CoV-2' named entity 'reduce inflammation' named entity 'TNF-α' named entity 'pathogens' named entity 'pulmonary syndrome' named entity 'NK cell' named entity 'Roivant Sciences' named entity 'cough' named entity 'CRS' named entity 'NK cell' named entity 'clinical trials' named entity 'anti-inflammatory' named entity 'lung' named entity 'COVID-19' named entity 'cytokines' named entity 'Cytokine storm' named entity 'IL-1 receptor antagonist' named entity 'anti-viral' named entity 'CD8 +' named entity 'clinical trials' named entity 'comorbidity' named entity 'COVID' named entity 'intensive care unit' named entity 'immune cells' named entity 'IgG' named entity 'viral load' named entity 'randomized clinical trials' named entity 'lung disease' named entity 'SARS-CoV-2 pandemic' named entity 'bispecific antibody' named entity 'monoclonal antibody' named entity 'IFN-γ' named entity 'convalescent plasma' named entity 'acute respiratory distress syndrome' named entity 'IgG1' named entity 'immunotherapies' named entity 'blood products' named entity 'IFN-γ' named entity 'ARDS' named entity 'conformation' named entity 'lymphocyte count' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'CD14' named entity 'seroconverted' named entity 'SARS-CoV-2' named entity 'lungs' named entity 'receptor' named entity 'tocilizumab' named entity 'CRP'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software